A Study of LY3971297 in Healthy Participants
Completed · Phase 1 · NCT06148272
Conditions: Healthy, Obesity, Hypertension
At a glance
- Research payments reported, 2025
- $3.6M
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 200
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3971297 (drug), Placebo (drug), LY3971297 IV (drug)
- Dates
- Started 2023-12-07; completion 2026-08-18
- Results posted
- Not yet
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.
From ClinicalTrials.gov, last updated 2026-09-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.6M in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amina Z. Haggag, M.D. Family Medicine · Northridge, CA
- Cassandra C. Key, M.D. Internal Medicine · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Anaheim Clinical Trials LLC $3.6M
- Icon Early Phase Services $8,757
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.